Regeneron (REGN) jumps on robust Q4 earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Regeneron beats fourth-quarter revenue estimates
February 2, 2024 6:49 AM EST(Reuters) -Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target.
Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.
... MoreRegeneron (REGN) Tops Q4 EPS by 109c
February 2, 2024 6:34 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $11.86, $1.09 better than the analyst estimate of $10.77. Revenue for the quarter came in at $3.43 billion versus the consensus estimate of $3.3 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More